Phage Display's Prospects for Early Diagnosis of Prostate Cancer
- PMID: 38400052
- PMCID: PMC10892688
- DOI: 10.3390/v16020277
Phage Display's Prospects for Early Diagnosis of Prostate Cancer
Abstract
Prostate cancer (PC) is the second most diagnosed cancer among men. It was observed that early diagnosis of disease is highly beneficial for the survival of cancer patients. Therefore, the extension and increasing quality of life of PC patients can be achieved by broadening the cancer screening programs that are aimed at the identification of cancer manifestation in patients at earlier stages, before they demonstrate well-understood signs of the disease. Therefore, there is an urgent need for standard, sensitive, robust, and commonly available screening and diagnosis tools for the identification of early signs of cancer pathologies. In this respect, the "Holy Grail" of cancer researchers and bioengineers for decades has been molecular sensing probes that would allow for the diagnosis, prognosis, and monitoring of cancer diseases via their interaction with cell-secreted and cell-associated PC biomarkers, e.g., PSA and PSMA, respectively. At present, most PSA tests are performed at centralized laboratories using high-throughput total PSA immune analyzers, which are suitable for dedicated laboratories and are not readily available for broad health screenings. Therefore, the current trend in the detection of PC is the development of portable biosensors for mobile laboratories and individual use. Phage display, since its conception by George Smith in 1985, has emerged as a premier tool in molecular biology with widespread application. This review describes the role of the molecular evolution and phage display paradigm in revolutionizing the methods for the early diagnosis and monitoring of PC.
Keywords: PC; affinity selection; electrochemical biosensor; electrochemical impedance spectroscopy; enzyme-linked immunosorbent assay (ELISA); free-prostate-specific antigen (F-PSA); label-free immunosensor; landscape phage; molecular evolution; phage ELISA; phage capture assay; phage display; prostate-specific antigen (PSA); prostate-specific matrix antigen (PSMA); recombinant antibodies; total-prostate-specific antigen (t-PSA).
Conflict of interest statement
The author declares no conflicts of interest.
Figures












Similar articles
-
Selected landscape phage probe as selective recognition interface for sensitive total prostate-specific antigen immunosensor.Biosens Bioelectron. 2018 May 30;106:1-6. doi: 10.1016/j.bios.2018.01.046. Biosens Bioelectron. 2018. PMID: 29414074
-
Specific probe selection from landscape phage display library and its application in enzyme-linked immunosorbent assay of free prostate-specific antigen.Anal Chem. 2014 Mar 4;86(5):2767-74. doi: 10.1021/ac404189k. Epub 2014 Feb 18. Anal Chem. 2014. PMID: 24533565
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?Hell J Nucl Med. 2012 Sep-Dec;15(3):241-6. Hell J Nucl Med. 2012. PMID: 23227460 Review.
-
Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.Am J Ther. 2004 Nov-Dec;11(6):501-6. doi: 10.1097/01.mjt.0000141604.20320.0c. Am J Ther. 2004. PMID: 15543092 Review.
References
-
- Chhikara B.S., Parang K. Global Cancer Statistics 2022: The trends projection analysis. Chem. Biol. Lett. 2023;10:451
-
- Hugosson J., Roobol M.J., Mansson M., Tammela T.L.J., Zappa M., Nelen V., Kwiatkowski M., Lujan M., Carlsson S.V., Talala K.M., et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur. Urol. 2019;76:43–51. doi: 10.1016/j.eururo.2019.02.009. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous